Primary medication nonadherence is a widespread public health problem; however, the subject lacks standardized definitions and measures.
Primary medication nonadherence is a widespread public health problem; however, the subject lacks standardized definitions and measures making it difficult to establish the true extent of the problem and track changes over time.
In a study published in Journal of Managed Care and Specialty Pharmacy (JMCP) Alex Adams, PharmD, MPH, and Samuel Stolpe, PharmD, compiled set parameters for a new industry measure.
Study Objectives
Primary and secondary nonadherence are distinct subsets of medication non-adherence.
Since most medication adherence research to date has focused on secondary non-adherence, PMN has been identified as a major research gap. There are lack of standardized measures and limited understanding of its true extent. Adams and Stolpe have tried to establish more standardized PMN measures so that it might be helpful in benchmarking and quality improvement initiatives.
For the study, a literature review was conducted using Google Scholar and PubMed databases, covering the time period from 1990 to June 2015. Search terms included “primary non-adherence,” “primary medication non-adherence,” “medication non-redemption,” “medication non-fulfillment,” “primary non-compliance,” “first-fill prescriptions,” and “newly initiated drug therapy.”
Clarity on Terminology
The most frequently used terms (in 77% of all studies) to describe PMN were “primary medication nonadherence” or “primary adherence.” Three studies used the term “prescription abandonment” for the same. But PMN is not the same as prescription abandonment. “Prescription abandonment” is traditionally used in studies as a broader term than PMN and occurs whenever a prescription is filled by a pharmacy but not claimed by the patient.
“PMN occurs when a new medication is prescribed for a patient, but the patient does not obtain the medication, or appropriate alternative, within an acceptable period of time after it was prescribed,” the authors wrote.
Standardization Leads to Effectiveness
Poor medication adherence is an increasing public health issue that has been linked to worse health outcomes, increased hospitalizations, and increased health care costs. Medication nonadherence is responsible for a cost of $290 billion annually in the United States.
It is very important to develop a consensus-based definition and quality measure of PMN. Doing that would enable one step closer towards consistent measurement of this phenomenon. Especially since e-prescribing is becoming the leading mode of prescription transmission, it is important to have standardized methods of tracking PMN in order to study the effectiveness of interventions to reduce PMN.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More